How successful is Mounjaro for weight loss in the UK?

What 'success' on Mounjaro actually looks like in trial data

The SURMOUNT-1 trial is the primary reference. Over 72 weeks, participants using tirzepatide at 15mg lost an average of around 20–21% of starting body weight. At lower maintenance doses the averages were lower: approximately 15% at 5mg and around 19.5% at 10mg. NICE's appraisal of tirzepatide (TA1026) cites these figures when making the case for its recommendation, and they're reproducible across the SURMOUNT programme's several thousand participants. For context, the NHS notes that a clinically meaningful weight loss is typically 5–10% of starting weight; tirzepatide's average at the higher doses is substantially above that bar. The question isn't whether Mounjaro 'works' in the statistical sense — the evidence is settled. The question is how it works for you, which brings in biology, dose, duration, lifestyle and adherence. You can read more about the underlying mechanism and trial programme on our tirzepatide overview.

A question our prescribers hear most weeks is some version of: 'How much will I actually lose?' The honest answer is that the trial averages are real averages, half of participants lost more than that figure, half lost less. Some people on 10mg or 15mg lose 25–30% of their weight; some on the same dose lose 10%. If you want to see what that range can look like in practice, our Mounjaro weight loss success story page gives a grounded example of how one person's journey unfolded across doses. The biology of individual response to GLP-1 and GIP pathways isn't yet predictable from a baseline blood test.

The factors that shape your result

Success on Mounjaro isn't passive. The SURMOUNT trials paired the medicine with a reduced-calorie diet and increased physical activity, that's also the condition under which it holds its UK licence. People who make meaningful lifestyle changes alongside treatment tend to see better and more sustained results. That's not moralising; it's pharmacology. The medicine reduces appetite significantly, which makes dietary change easier to sustain than it is for most people without medication, but it doesn't replace the changes themselves.

Dose matters too. Starting at 2.5mg (the tolerability dose, its job is settling your system, not treating weight), most people titrate upward every four weeks under prescriber guidance. Those who reach and tolerate higher doses generally see greater loss. Stopping treatment early, before reaching a stable maintenance dose, tends to blunt outcomes. If you're trying to understand how different dose stages compare, our page on Mounjaro weight loss success covers that ground in more detail.

Health conditions also shape response. Type 2 diabetes, for example, is associated with somewhat lower average weight loss than in people without it, still clinically significant, but worth knowing. Your prescriber factors all of this in during assessment. At nume, that assessment is done by a GPhC-registered Independent Prescriber on the same day you apply, not by an automated system.

When Mounjaro is considered less successful, and what the guidance says

NICE's recommendation includes a review point: if you haven't lost at least 5% of your starting weight after six months at your highest tolerated dose, the prescriber should reconsider whether continuing is appropriate. That's a meaningful threshold, not an arbitrary one, it separates people whose biology responds well from those for whom a different approach may be better suited. It's also worth knowing that the medicine needs time. Expecting significant loss in the first four to six weeks, while your body is still adjusting on the lower starter doses, sets an unrealistic benchmark.

Side effects can affect success indirectly. Persistent nausea, for instance, sometimes makes it harder to eat enough protein, which matters for preserving muscle mass during loss. Titrating slowly (staying on a lower dose for longer if needed) often helps. The NHS tirzepatide page has a clear rundown of common side effects and when to seek medical advice. Most GI symptoms ease within the first couple of weeks at any given dose; they're a poor reason to stop treatment, but a good reason to talk to your prescriber before doing so. For rarer side effects like visual changes, our tirzepatide and eyes page explains what the current evidence says.

Understanding the Mounjaro success rate across the wider population can help calibrate expectations before you start.

Putting success in context: how Mounjaro compares and what it means practically

Compared with the previous generation of weight-loss medicines, Mounjaro's average results are substantially higher. Semaglutide 2.4mg (Wegovy) produced around 15% average loss in the STEP 1 trial at 68 weeks, itself a significant advance over what was possible before GLP-1 medicines arrived. In the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. You can see a detailed comparison on our weight loss treatments overview.

Practically, a 20% reduction in body weight for someone starting at 120kg means losing roughly 24kg. For many people, that's a transformation in joint health, blood pressure, sleep apnoea severity and metabolic markers, not just a clothing size. The NHS characterises Mounjaro as a medicine for weight management, not cosmetic use, and the NICE recommendation reflects that clinical framing.

Real-world accounts can be useful (our Mounjaro success stories page curates what people have reported) but they're illustrative, not predictive. Your result depends on your biology, your dose journey and your context. If you're weighing up whether to start, a conversation with a prescriber is the right next step. You can check your eligibility with a free consultation, reviewed by a prescriber the same day.